402 related articles for article (PubMed ID: 17479104)
1. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.
Hoffmann D; Wildner O
Cancer Gene Ther; 2007 Jul; 14(7):627-39. PubMed ID: 17479104
[TBL] [Abstract][Full Text] [Related]
2. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.
Hoffmann D; Meyer B; Wildner O
J Gene Med; 2007 Sep; 9(9):764-78. PubMed ID: 17640083
[TBL] [Abstract][Full Text] [Related]
3. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
Hoffmann D; Bangen JM; Bayer W; Wildner O
Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
[TBL] [Abstract][Full Text] [Related]
4. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs.
Wildner O; Hoffmann D; Jogler C; Uberla K
Cancer Gene Ther; 2003 Oct; 10(10):791-802. PubMed ID: 14502232
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells.
Gupta V; Wang W; Sosnowski BA; Hofman FM; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E26. PubMed ID: 16709032
[TBL] [Abstract][Full Text] [Related]
7. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
[TBL] [Abstract][Full Text] [Related]
8. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma.
Geoerger B; Vassal G; Opolon P; Dirven CM; Morizet J; Laudani L; Grill J; Giaccone G; Vandertop WP; Gerritsen WR; van Beusechem VW
Cancer Res; 2004 Aug; 64(16):5753-9. PubMed ID: 15313916
[TBL] [Abstract][Full Text] [Related]
10. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
11. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
13. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma.
Zheng S; Ulasov IV; Han Y; Tyler MA; Zhu ZB; Lesniak MS
J Gene Med; 2007 Mar; 9(3):151-60. PubMed ID: 17351980
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic adenoviral therapy for glioblastoma multiforme.
Sonabend AM; Ulasov IV; Han Y; Lesniak MS
Neurosurg Focus; 2006 Apr; 20(4):E19. PubMed ID: 16709024
[TBL] [Abstract][Full Text] [Related]
16. HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation.
Saydam O; Saydam N; Glauser DL; Pruschy M; Dinh-Van V; Hilbe M; Jacobs AH; Ackermann M; Fraefel C
Gene Ther; 2007 Aug; 14(15):1143-51. PubMed ID: 17495946
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma.
Hoffmann D; Heim A; Nettelbeck DM; Steinstraesser L; Wildner O
Hum Gene Ther; 2007 Jan; 18(1):51-62. PubMed ID: 17184155
[TBL] [Abstract][Full Text] [Related]
18. Locoregional delivery of adenoviral vectors.
ter Horst M; Verwijnen SM; Brouwer E; Hoeben RC; de Jong M; de Leeuw BH; Sillevis Smitt PA
J Nucl Med; 2006 Sep; 47(9):1483-9. PubMed ID: 16954557
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse.
Paielli DL; Wing MS; Rogulski KR; Gilbert JD; Kolozsvary A; Kim JH; Hughes J; Schnell M; Thompson T; Freytag SO
Mol Ther; 2000 Mar; 1(3):263-74. PubMed ID: 10933942
[TBL] [Abstract][Full Text] [Related]
20. Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors.
Shashkova EV; Cherenova LV; Kazansky DB; Doronin K
Cancer Gene Ther; 2005 Jul; 12(7):617-26. PubMed ID: 15761475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
